Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03582267 · ClinicalTrials.gov registry record · NA
The Effect of Docosahexaenoic Acid Supplementation on Biomarkers of Concussion Over the Course of a Year in Canadian National Rugby Players
A NA study, sponsored by Texas Christian University.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT03582267 is a NA study that has completed, run by Texas Christian University. The registered enrollment target is 50 participants.
The verdict
NCT03582267, a NA study, has completed, sponsored by Texas Christian University.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
Nutrition interventions may present a safe and relatively risk free intervention for protection against subconcussive impacts. Docosahexaenoic acid (DHA, 22:6n-3) is the principal Omega 3 polyunsaturated fatty acid in the brain, playing an integral role in the brain's development and structural integrity. The goal of this study is to determine if supplementation with DHA attenuates blood biomarkers of repetitive head trauma linked to sub-concussive impacts sustained in rugby participation.
Interventions
- DIETARY_SUPPLEMENT Docosahexaenoic Acid (DHA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2019-08-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03582267
The ClinicalTrials.gov registry entry for NCT03582267 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Christian University, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Docosahexaenoic Acid (DHA) is the first listed.
NCT03582267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03582267 about?
NCT03582267 is a clinical study titled "The Effect of Docosahexaenoic Acid Supplementation on Biomarkers of Concussion Over the Course of a Year in Canadian National Rugby Players". Nutrition interventions may present a safe and relatively risk free intervention for protection against subconcussive impacts. Docosahexaenoic acid (DHA, 22:6n-3) is the principal Omega 3 polyunsaturated fatty acid in the brain, playing an integral role in the brain's development and structural inte...
What is the current status of trial NCT03582267?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2017-08-01. Estimated completion is 2019-08-01.
What interventions are being tested in trial NCT03582267?
The interventions under investigation include: Docosahexaenoic Acid (DHA) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03582267?
This trial is sponsored by Texas Christian University, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.